Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer
Authors
Keywords
Luteolin, Apigenin, KRAS, PD-L1/PD-1, Lung cancer, STAT3
Journal
CANCER LETTERS
Volume 515, Issue -, Pages 36-48
Publisher
Elsevier BV
Online
2021-05-28
DOI
10.1016/j.canlet.2021.05.019
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- In situ antitumor vaccination: Targeting the tumor microenvironment
- (2020) Hanwen Li et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-γ-signaling mutant cancer cells
- (2020) Jason B. Williams et al. Nature Communications
- Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma
- (2020) Elena Galvani et al. Nature Communications
- PD-1+ natural killer cells in human non-small cell lung cancer can be activated by PD-1/PD-L1 blockade
- (2020) Marcel P. Trefny et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Oncogenic driver genes and tumor microenvironment determine the type of liver cancer
- (2020) Gang Wang et al. Cell Death & Disease
- Dolutegravir derivative inhibits proliferation and induces apoptosis of non-small cell lung cancer cells via calcium signaling pathway
- (2020) Wen-Jun Wang et al. PHARMACOLOGICAL RESEARCH
- Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
- (2019) Xianjie Jiang et al. Molecular Cancer
- A CD40 agonist and PD-1 antagonist antibody reprogram the microenvironment of non-immunogenic tumors to allow T cell-mediated anticancer activity
- (2019) Hayley S. Ma et al. Cancer Immunology Research
- Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer
- (2019) Patrick R. Halliday et al. Current Oncology Reports
- The Combination of MEK inhibitor with Immunomodulatory Antibodies Targeting PD-1 and PD-L1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer
- (2019) Jong Woo Lee et al. Journal of Thoracic Oncology
- The Therapeutic Potential of Apigenin
- (2019) Bahare Salehi et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Identification of a new inhibitor of KRAS-PDEδ interaction targeting KRAS mutant nonsmall cell lung cancer
- (2019) Elaine Lai-Han Leung et al. INTERNATIONAL JOURNAL OF CANCER
- Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy
- (2019) Tuba N. Gide et al. CANCER CELL
- IL23-Producing Human Lung Cancer Cells Promote Tumor Growth via Conversion of Innate Lymphoid Cell 1 (ILC1) into ILC3
- (2019) Jaemoon Koh et al. CLINICAL CANCER RESEARCH
- Advancing Biomarker Development Through Convergent Engagement: Summary Report of the 2nd International Danube Symposium on Biomarker Development, Molecular Imaging and Applied Diagnostics; March 14–16, 2018; Vienna, Austria
- (2019) M. S. Lim et al. MOLECULAR IMAGING AND BIOLOGY
- Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer
- (2019) Hyejin Choi et al. Cell Reports
- Luteolin modulates gene expression related to steroidogenesis, apoptosis, and stress response in rat LC540 tumor Leydig cells
- (2019) Roxanne Couture et al. CELL BIOLOGY AND TOXICOLOGY
- circTP63 functions as a ceRNA to promote lung squamous cell carcinoma progression by upregulating FOXM1
- (2019) Zhuoan Cheng et al. Nature Communications
- Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?
- (2019) Rui-Mei Feng et al. Cancer Communications
- Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations
- (2019) Anqi Lin et al. Molecular Cancer
- Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer
- (2019) Fan Luo et al. Journal for ImmunoTherapy of Cancer
- A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo
- (2019) Longchuan Bai et al. CANCER CELL
- Tissue-resident memory CD8+ T cells amplify anti-tumor immunity by triggering antigen spreading through dendritic cells
- (2019) Evelyn Menares et al. Nature Communications
- Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies
- (2019) José Medina-Echeverz et al. Nature Communications
- The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity
- (2019) Chengming Liu et al. CANCER LETTERS
- The ROS-KRAS-Nrf2 axis in the control of the redox homeostasis and the intersection with survival-apoptosis pathways: Implications for photodynamic therapy
- (2019) Annalisa Ferino et al. JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY
- Antibacterial Activity of Some Flavonoids and Organic Acids Widely Distributed in Plants
- (2019) Artur Adamczak et al. Journal of Clinical Medicine
- Tumor-infiltrating B cells: their role and application in anti-tumor immunity in lung cancer
- (2018) Si-si Wang et al. Cellular & Molecular Immunology
- Interferon γ and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity
- (2018) Elise Alspach et al. Cold Spring Harbor Perspectives in Biology
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Plumbagin from a tropical pitcher plant (Nepenthes alata Blanco) induces apoptotic cell death via a p53-dependent pathway in MCF-7 human breast cancer cells
- (2018) Umasankar De et al. FOOD AND CHEMICAL TOXICOLOGY
- Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects
- (2018) Lu Xu et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- The Dark Side of IFN-γ: Its Role in Promoting Cancer Immunoevasion
- (2017) Marija Mojic et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
- (2017) Marian L. Burr et al. NATURE
- MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer
- (2017) A Bouillez et al. ONCOGENE
- Apigenin in cancer therapy: anti-cancer effects and mechanisms of action
- (2017) Xiaohui Yan et al. Cell and Bioscience
- Cancer statistics in China, 2015
- (2016) Wanqing Chen et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Apigenin inhibits the inducible expression of programmed death ligand 1 by human and mouse mammary carcinoma cells
- (2016) Melanie R. Power Coombs et al. CANCER LETTERS
- STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment
- (2016) S. Koyama et al. CANCER RESEARCH
- Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
- (2013) E. A. Akbay et al. Cancer Discovery
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More